Journal of Medical Biochemistry最新文献

Background: Coronary heart disease (CHD) is a leading cause of morbidity among elderly populations, with inflammation and cardiac dysfunction indicated by elevated MCP-1 and NT-proBNP levels. This study evaluated the effects of integrating Traditional Chinese Medicine (Baoyuan and Taohong Siwu decoctions) with standard Western therapy on serum MCP-1 and NT-proBNP in elderly CHD patients. Results demonstrated significant reductions in these biomarkers, supporting the complementary role of TCM in managing CHD.

Methods: A total of 90 elderly CHD patients were randomly allocated into two groups (n=45 each): the control group (CG), receiving conventional Western medicine alone, and the research group (RG), treated with BYD-THSWD combined with standard Western pharmacotherapy. Serum levels of MCP-1 and NT-proBNP, lipid profiles (TG, TC, LDL-C, HDL-C), and clinical symptoms (chest pain, chest tightness, fatigue, sweating) were assessed at baseline and after 1, 2, and 3 months of treatment. Statistical comparisons between groups were conducted using independent-sample t-tests and chi-square tests.

Results: After 3 months, serum levels of MCP-1 (113.09±5.49 vs. 126.38±7.04 pg/mL, P<0.05) and NT-proBNP (614.28±54.77 vs. 781.28±68.29 ng/mL, P<0.05) were significantly lower in the RG compared to the CG. Similarly, the RG exhibited significantly improved lipid profiles and greater symptomatic relief, reflected by significantly lower TCM symptom scores for chest pain, chest tightness, fatigue, and sweating compared to the CG at all post-treatment intervals (all P<0.05).

Conclusions: Integrating Baoyuan decoction and Taohong Siwu decoction with conventional Western medicine significantly reduces MCP-1 and NT-proBNP levels, improves lipid metabolism, and alleviates clinical symptoms in elderly coronary heart disease patients. These findings highlight the potential of Traditional Chinese Medicine as a complementary therapy in enhancing standard CHD treatment outcomes.

Background: Acute cerebral infarction (ACI) is a frequent type of stroke disease in clinical practice. Cognitive dysfunction is a common complication of ACI, which severely influences the quality of life of patients. Objective: To evaluate the effects of butylphthalide sequential therapy on inflammatory markers (PTX-3, S100B, IL-6) and cognitive outcomes in patients with acute cerebral infarction (ACI).

Methods: From March 2023 to March 2024, 120 patients with ACI combined with cognitive dysfunction diagnosed and treated in our hospital were randomly divided into a control group (CG) and an observation group (OG). The clinical effective rate, MMSE scores, NIHSS scores, Barthel index scores, levels of inflammatory factors, and incidence of complications in both groups were compared.

Results: Compared to the CG, the total effective rate of the OG was higher (c2=4.90, P<0.05). MMSE scores and Barthel index scores were elevated in both groups 2 weeks and 2 months after treatment, and those in the OG were higher relative to the CG (P<0.05). NIHSS scores and hs-CRP, as well as PTX-3 levels, declined in both groups 2 weeks and 2 months after treatment, and those in the OG were lessened compared to the CG (P<0.05). The occurrence of complications in the OG was reduced relative to the CG (P<0.05). Serum analysis showed lower hs-CRP, PTX-3, and IL-6 levels in the OG (P<0.05), suggesting reduced inflammation with butylphthalide therapy. While S100B levels showed a non-significant decline, albumin levels remained unchanged, indicating no significant impact on neuronal injury or nutritional recovery (P>0.05).

Conclusions: Butylphthalide sequential therapy can promote the neurological function as well as living ability of patients with ACI combined with cognitive dysfunction, with high safety, which is valuable for clinical promotion.

Background: This study aims to evaluate the effects of high-quality nursing combined with immune-type enteral nutrition (IEN) support on postoperative recovery, nutritional status, immune function, inflammatory response, and complication rates in patients undergoing radical colon cancer resection.

Methods: A total of 106 patients with colon cancer who underwent radical resection were randomly divided into a control group (CG) and an observation group (OG). The CG received routine nursing care and parenteral nutrition support, while the OG received high-quality nursing care and immune-type enteral nutrition support. Key outcomes were assessed, including recovery times, nutritional markers, immune function, inflammatory response, quality of life (QLQ-C30 scores), complication incidence, and nursing satisfaction.

Results: The OG demonstrated significantly shorter recovery times for bowel sounds, exhaust gas, defecation, time to get out of bed, and overall hospital stay compared to the CG (P<0.05). The incidence of complications was also lower in the OG (3.77% vs. 16.98%, P=0.025). Nutritional markers such as serum transferrin (TFN), prealbumin (PA), and albumin (ALB) were significantly higher in the OG (P<0.05), along with increased levels of immunoglobulins (IgG, IgA, and IgM) and reduced inflammatory markers (CRP and IL-6, P<0.05). Quality of life scores and nursing satisfaction were significantly better in the OG (P<0.05).

Conclusions: High-quality nursing combined with immune-type enteral nutrition support significantly enhances postoperative recovery, improves nutritional and immune status, reduces inflammation, lowers complication rates, and boosts the quality of life and nursing satisfaction in patients undergoing radical resection for colon cancer. This approach provides an effective strategy for promoting better outcomes in this patient population.

Background: Alzheimer's disease (AD) is a degenerative disease of the central nervous system characterized by neuroinflammation and amyloid deposition. Folic acid (FA), a B vitamin, may improve the course of AD by modulating inflammation and neuroprotection. This study aimed to investigate the effects of FA supplementation on serum inflammatory cytokines (IL-1b, IL-6, TNF-a), amyloid (Ab1-42), Tau proteins, and neurotransmitters (GABA, 5-HT, Ach) in AD patients.

Methods: We conducted a follow-up-controlled trial; 114 AD patients were included and randomly divided into a control group (donepezil treatment) and an experimental group (donepezil + FA treatment) for 3 months. Inflammatory factors, Ab1-42, Tau, neurotransmitter levels and nutritional status were assessed before and after treatment.

Results: The total effective rate of the experimental group (89.47%) was significantly higher than that of the control group (75.44%), and the levels of inflammatory factors (IL-1b, IL-6, and TNF-a), Ab1-42, and Tau were significantly lower (P<0.05), and neurotransmitters (GABA, 5-HT, and Ach) and nutritional indexes (albumin and hemoglobin) were substantially higher.

Conclusions: FA supplementation can effectively delay AD progression by inhibiting neuroinflammation, reducing amyloid deposition, regulating neurotransmitter metabolism and improving nutritional status.

Background: This study aimed to identify novel methyla-tion-based prognostic biomarkers for endometrial cancer (EC) to facilitate early diagnosis and treatment. To explore methylation-related prognostic markers in endometrial tis-sue by analyzing TCGA data and to establish a methylation-based risk model for EC patients.

Methods: We systematically analyzed methylation-related gene expression and prognostic significance in 409 EC patients using TCGA DNA methylation data. DNA methy-lation biomarkers were identified through consensus clus-tering and weighted gene co-expression network analysis (WGCNA). The clusterProfiler algorithm was employed to determine key signaling pathways across different sub-groups. A gene panel targeting critical DNA methylation sites was subsequently constructed.

Results: A methylation-related prognostic risk model was developed, incorporating five CpG sites: cg01416891, cg00082235, cg01493517,cg03811891,and cg05317207. The model demonstrated strong predictive performance, with high-risk patients exhibiting significantly poorer prog-noses compared to low-risk patients. A gene panel was also established to predict prognosis across different EC risk groups.

Conclusions: The methylation-related gene panel model serves as a reliable prognostic biomarker for EC, offering potential for enhanced early diagnosis and personalized treatment strategies.

Background: To observe the relationship between the expression of serum interleukin-6 (IL-6) and neutrophil/lymphocyte ratio (NLR) and the prognosis of patients with acute liver failure (ALF) treated with artificial liver.

Methods: 80 patients with ALF from January 2021 to October 2023 were included. All of them received artificial liver system treatment. All of the included subjects completed the effective follow-up for three months. The patients were followed up until April 30, 2023. According to the disease outcomes of patients after the end of follow-up, they were divided into a survival group and a death group. The serum IL-6 and NLR expressions of the two groups were compared, and the relationship between serum IL-6 and NLR expressions and the prognosis of patients with ALF treated with artificial liver was analysed.

Results: The expression levels of serum IL-6 and NLR in the death group were higher (P<0.05). The high expressions of serum IL-6 and NLR might be a risk factor for the increased risk of death in patients with ALF after treatment (P<0.05). The receiver operating characteristic (ROC) curve indicated that the area under the curve (AUC) of fasting serum IL-6 and NLR expressions in patients with ALF predicting the prognosis of artificial liver treatment were 0.727 and 0.789. When the AUC of serum IL-6 combined with NLR predicted the prognosis of artificial liver treatment in patients with ALF, it was 0.889.

Conclusions: The expression of serum IL-6 and NLR is correlated with the prognosis of patients with ALF treated with artificial liver.

Background: This study investigates the effects of Ginkgo Diterpene Lactone Meglumine (GM) combined with Clopidogrel (CLO) on hemodynamics, neurocytokines, and inflammatory responses in patients with cerebral infarction (CI) complicated by coronary heart disease (CHD).

Methods: A total of 152 patients diagnosed with CI complicated by CHD, admitted to our hospital between January 2024 and October 2024, were enrolled in the study. Among them, 81 patients received CLO monotherapy (control group), while the remaining 71 patients were treated with a combination of CLO and GM (observation group). Hemodynamic parameters, including plasma viscosity (PV), whole blood high (WBHSV) and low shear viscosity (WBLSV), as well as reduced viscosity (RV), were measured before and after treatment. Platelet adhesion test (PAdT) and platelet aggregation test (PAgT) were also performed. Inflammatory markers and neurocytokines were assessed using enzyme-linked immunosorbent assays, and adverse reactions during treatment were documented.

Results: After treatment, both groups exhibited significant reductions in PAdT, PAgT, PV, WBHSV, WBLSV, and RV compared to baseline (P<0.05). However, PAdT, PAgT, WBHSV, WBLSV and RV were lower in the observation group compared to the control group (P<0.05). Additionally, the observation group showed lower levels of neuron-specific enolase, glial fibrillary acidic protein, tumor necrosis factor-a, and hypersensitive C-reactive protein, along with higher levels of brain-derived neurotrophic factor, compared to the control group (P<0.05). No significant difference was observed in the incidence of adverse reactions between the two groups (P>0.05).

Conclusions: The combination of GM and CLO is more effective than CLO monotherapy in improving hemodynamics, enhancing neurological function, and mitigating inflammatory responses in patients with CI complicated by CHD.

Background: This study aimed to develop a risk score model for predicting acute kidney injury (AKI) in children with sepsis, using red blood cell distribution width (RDW), Acute Physiology and Chronic Health Evaluation II (APACHE II) score, and additional biomarkers (PCT, IL-6, CRP, and cystatin C) based on logistic regression (LR) analysis.

Methods: Children treated in the ICU of The First Affiliated Hospital of Xinjiang Medical University from July 2021 to August 2022 were enrolled. The experimental group (Exp) included 155 children with sepsis, while the control group (Ctrl) consisted of 70 children. LR analysis was employed to identify factors associated with AKI risk. The Exp was further divided into two subgroups: the routine group (RG, n=77) and the intervention group (IG, n=78). The IG received intervention based on the risk score model, while the RG received routine treatment. Receiver operating characteristic (ROC) curves were used for diagnostic evaluation.

Results: The two groups observed significant differences in white blood cell count (WBC) and RDW levels. The development of AKI in sepsis patients was strongly associated with RDW, APACHE II score, and the biomarkers PCT, IL-6, CRP, and cystatin C. After the intervention, the incidence of AKI and AKI grade 3 significantly decreased, along with lower rates of renal replacement therapy and mortality.

Conclusions: The LR-based model integrating RDW, APACHE II score, and biomarkers (PCT, IL-6, CRP, cystatin C) effectively predicts the risk of AKI in children with sepsis, offering a valuable tool for early intervention and improved patient outcomes.

Background: The study aimed to assess antioxidative status using standard biochemical analyses in multiple sclerosis patients during relapse and remission. Also, to evaluate the effects of gender, drug-modified treatment and clinical characteristics of multiple sclerosis on analyzed antioxidants.

Methods: The study consisted of 178 relapse-remitting multiple sclerosis patients (61 relapse/117 remission), 93 females and 85 males, with a mean age of 40.9±9.8 (average age of 40.9) and 80 matched healthy controls. Ongoing drug-modified treatment received 132 patients. The serum levels of uric acid, total bilirubin, albumin, and transferrin were analyzed in both patients and controls. Extended Disability Status Scale (EDSS), disease duration and annual relapse rate were used as clinical characteristics of multiple sclerosis.

Background: Oxidative stress (OS) plays a crucial role in colorectal cancer (CRC) progression. Lactobacillus has been proposed as a potential modulator of OS. This randomised controlled trial aimed to evaluate the effects of Lactobacillus supplementation on OS markers and its related signalling pathways in CRC patients after surgery.

Methods: A total of 76 CRC patients were enrolled and randomised into two groups: the study group (n=39) received Lactobacillus supplementation, while the control group (n=37) received a placebo. The intervention lasted for six months following surgery. Serum levels of catalase (CAT), glutathione (GSH), oxidised glutathione (GSSG), 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG), and F2-isoprostanes (F2-IsoPs) were measured. In addition, the nuclear factor erythroid 2-related factor 2/Kelch-like ECH-associated protein 1 (NRF2/KEAP1), p38 mitogen-activated protein kinase (MAPK), and c-Jun N-terminal kinase (JNK) signalling pathways were assessed via western blot analysis.

Results: Following Lactobacillus supplementation, serum carcinoembryonic antigen (CEA) levels significantly decreased, whereas carbohydrate antigen 19-9 (CA19-9) levels remained unchanged. OS marker analysis demonstrated increased CAT, GSH, and F2-IsoPs levels and decreased GSSG and 8-oxodG levels in the study group compared to the control group. Western blot results revealed that NRF2, ASK1, MKK3, p-p38, and MKK4 protein levels were significantly reduced after Lactobacillus intervention, while KEAP1 and p-JNK remained unchanged.

Conclusions: Oral administration of Lactobacillus for six months reduced OS marker levels and inhibited NRF2/KEAP1, p38 MAPK, and JNK signalling pathways in CRC patients after surgery. These findings suggest that Lactobacillus may contribute to CRC management by modulating oxidative stress.